United Therapeutics (UTHR) Reports In-Line Q4 EPS, Beats on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $538.30 +0.32%
EPS Growth %: +12.6%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +12.6%
Financial Fact:
Cost of product sales: 23.6M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.89, in-line with the analyst estimate of $3.89. Revenue for the quarter came in at $464.7 million versus the consensus estimate of $420.9 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- Pfizer lung cancer drug misses survival goal in Phase 3 trial
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
